Smallpox drug: NDA submitted to FDA

SIGA Technologies, Inc. today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral formulation of TPOXX(R) (tecovirimat). TPOXX was developed to treat smallpox, as well as other orthopoxvirus infections. No cure or treatment for smallpox exists. The advanced development of TPOXX has been funded by the ["]

The post Smallpox drug: NDA submitted to FDA appeared first on Outbreak News Today.